In vitro measurement of avidity of radioiodinated antibodies.
A determination of the ability of radiolabeled antibodies to bind to their target antigen is an essential step in the initial selection of antibodies for clinical use as well as a quality control measure. In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity. Both assays were systematically influenced by target cell fixation and measurement of avidity was dependent on immunoreactivity. For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage. Thus, immunoreactivity and avidity assays are complementary and knowledge of both factors is required for the design of sensitive quality control procedures for radiolabeled antibodies.
D000818:Animals; D000906:Antibodies; D000936:Antigen-Antibody Complex; D002460:Cell Line; D007457:Iodine Radioisotopes; D007700:Kinetics; D008223:Lymphoma / Q000000981:diagnostic imaging*; D051379:Mice; D008815:Mice, Inbred Strains; D008954:Models, Biological; D011877:Radionuclide Imaging; D013601:T-Lymphocytes / Q000276:immunology
D000906:Antibodies; D000936:Antigen-Antibody Complex; D007457:Iodine Radioisotopes